November 5-6, 2013 | Boston Marriott Cambridge | Cambridge, MA
Drug discovery is a long, costly process with a high attrition rate, and a personalized medicine strategy is needed to improve clinical outcomes. Identifying the subclass of patients who is likely to respond to drugs and developing biomarkers for patient stratification before recruitment for clinical trials would improve efficacy and response rates. Cambridge Healthtech Institute’s Inaugural Biomarkers for Patient Stratification meeting will explore the integration of biomarkers and companion diagnostics into drug development, case studies of using biomarkers to guide clinical decision making, molecular profiling approaches and their impact on clinical development, as well as personalized medicine initiatives at big pharma.
- Molecular profiling of tumor heterogeneity
- Personalized medicine at big pharma
- Incorporating molecular diagnostics into drug development
- Biomarkers to guide therapy
Scientists who wish to present their knowledge and expertise to their colleagues are asked to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.
If you are interested in presenting, please click here to submit your proposal.
Deadline for submission is Friday, May 3, 2013
For more information, please contact:Julia Boguslavsky
Executive Director, Conferences
For sponsorship information, please contact:Ilana Quigley
Manager, Business Development